SPRR2A and ovarian carcinoma: In the trial of rhIL-12 in patients with ovarian cancer or peritoneal cancer, 3-fold or greater increases of IFNγ, TNFα, IL-10, IL-8, and vascular endothelial growth factor (VEGF) in the peritoneal fluid were observed post-rhIL-12 administration.